The role of government in the funding of clinical trials for the development of new therapeutics (drugs)

Supplementary Document

Year	NIH Budget (in billions USD)[1]	% Increase in Budget[1]	NIH Funding for Clinical Trials (in billions USD)[2]	FDA New Drug Approvals (NDAs)[3-6]	Orphan Designationated Drug (ODD)[3-6]	NIH-Supported Clinical Trials[7]	Notable Government Funded Projects
2010	31.23	-	3.1	21	7	1,428	Human Genome Project Research[8]
2011	30.91	-1.0%	3.1	30	12	1,310	Alzheimer's Disease Initiative[9]
2012	30.86	-0.2%	3.2	39	14	1,328	BRAIN Initiative[10]
2013	29.31	-5.0%	3.15	27	9	1,246	Precision Medicine Initiative[11]
2014	30.14	2.8%	3.2	41	15	1,290	Cancer Moonshot[12]
2015	30.31	0.6%	3.1	45	18	1,261	Ebola Vaccine Development[13]
2016	32.31	6.6%	3.5	22	9	1,280	Cancer Immunotherapy Research[14]
2017	34.30	6.2%	3.8	46	18	1,510	NIH All of Us Research Program[15]
2018	37.31	8.8%	5.2	59	31	1,552	Opioid Crisis Response Research[16]
2019	39.31	5.4%	6.1	48	21	1,687	Antibiotic Resistance Initiatives[17]
2020	41.69	6.0%	6.6	53	31	1,572	COVID-19 Vaccine Research[18]
2021	42.94	3.0%	6.5	50	26	1,844	Operation Warp Speed[19]
2022	46.18	7.5%	6.6	37	20	1,653	Long COVID Research[20]
2023	49.18	6.5%	6.8	55	28	1,678	Advancing Cancer Moonshot[21]

Table s1: Trends in NIH Funding, Clinical Trial Investments, and Drug Approvals (2010–2023)

References: -

1. Service CR. *The National Institutes of Health (NIH): Background and Congressional Issues*. 2023.
2. Health NIo. *Categorical Spending - NIH Research Portfolio Online Reporting Tools (RePORT)*. National Institutes of Health; 2024.
3. Brown DG, Wobst HJ. A decade of FDA-approved drugs (2010–2019): trends and future directions. *Journal of medicinal chemistry*. 2021;64(5):2312-2338.
4. Mullard A. 2020 FDA drug approvals. *Nature Reviews Drug Discovery*. 2021;20(2):85-91.
5. Food US, Administration D. *New Drug Therapy Approvals 2022*. 2023.
6. Senior M. Fresh from the biotech pipeline: record-breaking FDA approvals. *Nature Biotechnology*. 2024;
7. Health NIo. *NIH clinical research trials and you: Finding a clinical trial*. 2017.

8. Hood L, Rowen L. The human genome project: big science transforms biology and medicine. *Genome medicine*. 2013;5:1-8.
9. Rosow K, Holzapfel A, Karlawish JH, Baumgart M, Bain LJ, Khachaturian AS. Countrywide strategic plans on Alzheimer's disease: developing the framework for the international battle against Alzheimer's disease. *Alzheimer's & Dementia*. 2011;7(6):615-621.
10. Kandel ER, Markram H, Matthews PM, Yuste R, Koch C. Neuroscience thinks big (and collaboratively). *Nature Reviews Neuroscience*. 2013;14(9):659-664.
11. Ginsburg GS, Phillips KA. Precision medicine: from science to value. *Health affairs*. 2018;37(5):694-701.
12. Spivaka R. From the Heavens to the Helix: The Cost-Benefit Analysis of President Obama's "Moonshot" Call to Cure Cancer. *Journal of Science & Law| jscilaw org April*. 2017;4:1.
13. Folayan MO, Yakubu A, Haire B, Peterson K. Ebola vaccine development plan: ethics, concerns and proposed measures. *BMC Medical Ethics*. 2016;17:1-8.
14. Romero P, Banchereau J, Bhardwaj N, et al. The Human Vaccines Project: A roadmap for cancer vaccine development. *Science translational medicine*. 2016;8(334):334ps9-334ps9.
15. Sankar PL, Parker LS. The Precision Medicine Initiative's All of Us Research Program: an agenda for research on its ethical, legal, and social issues. *Genetics in Medicine*. 2017;19(7):743-750.
16. High PM, Marks K, Robbins V, et al. State targeted response to the opioid Crisis grants (opioid STR) program: Preliminary findings from two case studies and the national cross-site evaluation. *Journal of Substance Abuse Treatment*. 2020;108:48-54.
17. Anderson M, Schulze K, Cassini A, Plachouras D, Mossialos E. A governance framework for development and assessment of national action plans on antimicrobial resistance. *The Lancet Infectious Diseases*. 2019;19(11):e371-e384.
18. Attwell K, Carlson S, Tchilingirian J, et al. Coronavax: preparing community and government for COVID-19 vaccination: a research protocol for a mixed methods social research project. *BMJ open*. 2021;11(6):e049356.
19. Ho RJ. Warp-speed Covid-19 vaccine development: beneficiaries of maturation in biopharmaceutical technologies and public-private partnerships. *Journal of pharmaceutical sciences*. 2021;110(2):615-618.
20. Ziegler S, Raineri A, Nittas V, et al. Long COVID citizen scientists: developing a needs-based research agenda by persons affected by long COVID. *The Patient-Patient-Centered Outcomes Research*. 2022;15(5):565-576.
21. Shiels MS, Lipkowitz S, Campos NG, et al. Opportunities for achieving the Cancer Moonshot goal of a 50% reduction in cancer mortality by 2047. *Cancer discovery*. 2023;13(5):1084-1099.